Directory · JE
Pharmaceutical Manufacturing in Jersey
A register of firms and the professionals working at them in the Pharmaceutical Manufacturing sector based in Jersey. Browse the public index, then filter or export on Kipplo.
Companies
3 on file
Lv Pharmacy
Leading providers of innovative pharmacist-led services and driven by improving patient care. Specialist providers of services within care home and community care settings. Leading experts in dispensing of medicinal cannabis.
1 to 10 staff
Caprica
Caprica is a GMP accredited cultivator and processor of high THC medicinal cannabis, located in a square foot facility in Jersey that is capable of producing 3 to 4 tonnes of premium high THC dried cannabis flower per annum. Caprica was established in 2020 with a mission to produce only the highest quality cannabis product. In early 2022 Caprica completed its phase 1 build, creating a bespoke cleanroom cultivation and processing facility capable of delivering the highest degree of security and environmental control. Caprica uses a science and engineering led approach to produce medicinal cannabis product that maximises therapeutic potential for patients. Caprica has developed several high-quality cannabis genetics, tailored to patient needs. Caprica’s cleanroom facility, combined with its Quality Management System, ensures high quality medicinal cannabis product is produced regularly and consistently. Product exports begin in Q1 2025.
1 to 10 staff
Northern Leaf
At Northern Leaf, we deliver pharmaceutical-grade and EU-GMP-compliant medical cannabis for large-scale export to international markets. Operating one of Europe’s largest EU-GMP-licensed medical cannabis manufacturing facilities in the Channel Island of Jersey, Northern Leaf is committed to delivering a high-quality, consistent and compliant supply our partners can rely on. Following a change in leadership in 2024, the company has undergone a major turnaround, increasing capacity at its square ft facility from 25% to 75% in under two years. We are now entering our next growth stage and are focused on expansion into vertically integrated activities and on strengthening our portfolio with innovation and investment in pharmaceutical R&D, demonstrating our firm commitment to advancing the field of cannabis-based medicine. DISCLAIMER: We do not sell directly to patients or clinics.
11 to 50 staff
